MAM
CRVS icon

Meeder Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Meeder Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.5K Buy
6,055
+5,301
+703% +$73.6K ﹤0.01% 384
2026
Q1 		$11K Buy
+754
New +$12K ﹤0.01% 678
2022
Q3 		– Sell
-1,984
Closed -$2K – 2178
2022
Q2 		$2K Buy
1,984
+1,007
+103% +$1.24K ﹤0.01% 1874
2022
Q1 		$2K Buy
+977
New +$1.79K ﹤0.01% 2023
2021
Q4 		– Sell
-645
Closed -$3K – 1426
2021
Q3 		$3K Hold
645
– – ﹤0.01% 2064
2021
Q2 		$2K Hold
645
– – ﹤0.01% 2196
2021
Q1 		$2K Buy
+645
New +$2.33K ﹤0.01% 2062
2020
Q4 		– Sell
-645
Closed -$3K – 1947
2020
Q3 		$3K Buy
645
+37
+6% +$148 ﹤0.01% 1709
2020
Q2 		$2K Hold
608
– – ﹤0.01% 1754
2020
Q1 		$1K Sell
608
-1,480
-71% -$6.01K ﹤0.01% 2173
2019
Q4 		$11K Sell
2,088
-134
-6% -$469 ﹤0.01% 1532
2019
Q3 		$7K Buy
2,222
+1,216
+121% +$5.1K ﹤0.01% 1638
2019
Q2 		$4K Buy
1,006
+711
+241% +$2.79K ﹤0.01% 1712
2019
Q1 		$1K Sell
295
-1
-0.3% -$4 ﹤0.01% 1613
2018
Q4 		$1K Sell
296
-280
-49% -$1.91K ﹤0.01% 1621
2018
Q3 		$5K Buy
+576
New +$5.76K ﹤0.01% 1321
2018
Q2 		– Sell
-108
Closed -$1K – 1579
2018
Q1 		$1K Buy
108
+10
+10% +$95 ﹤0.01% 1447
2017
Q4 		$1K Buy
98
+21
+27% +$269 ﹤0.01% 1562
2017
Q3 		$1K Sell
77
-389
-83% -$5.38K ﹤0.01% 1538
2017
Q2 		$6K Buy
466
+245
+111% +$2.62K ﹤0.01% 1135
2017
Q1 		$5K Buy
+221
New +$3.46K ﹤0.01% 1060

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Meeder Asset Management's CRVS Position: Q2 2026 in Review

Meeder Asset Management increased its Corvus Pharmaceuticals (CRVS) stake by 703% in Q2 2026, buying an estimated $73.6K and bringing the position to 6,055 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

Meeder Asset Management first reported a position in CRVS in Q1 2017 and has held it in 21 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Meeder Asset Management held 6,055 shares of Corvus Pharmaceuticals worth $90.5K as of Q2 2026.
  • Meeder Asset Management bought 5,301 Corvus Pharmaceuticals shares in Q2 2026, an estimated $73.6K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #384 holding.
  • Meeder Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 21 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.